Stocks · News reference
SciSparc Subsidiary NeuroThera Labs Achieves Regulatory Milestone for Tourette Syndrome Clinical Trial
SciSparc's subsidiary, NeuroThera Labs, has completed manufacturing and obtained batch release certification for its SCI-110 drug candidate, enabling the start of patient enrollment in a Phase IIb clinical trial.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Surges Over 200 Points; Verizon Shares Fall Following Q3 Results
U.S. stocks rose Monday, led by the Dow’s 200-point gain. Consumer discretionary rallied, Verizon fell after mixed results, and oil dropped 1.2%.
SciSparc Unit NeuroThera Labs Issues Update On Its Clinical Trial Program Evaluating SCI-110 For Treatment Of Tourette Syndrome In Adults; Now Advancing Toward Patient Enrollment In Its Phase IIb Clinical Trial For TS, With Investigational Product Shipments To Study Sites Expected In The Near Term
SciSparc shares are trading lower after the company announced a strategic shift toward Agentic AI, cybersecurity, and finance technologies, noting there is no assurance the initiative will generate revenue.
SciSparc Shifts Strategic Focus To Agentic AI Powered Technologies, Including Cybersecurity And Finance Technologies
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.Building
SciSparc shares reversed earlier gains and are now trading lower after the company disclosed an inducement agreement to convert ~$2.02 million of outstanding principal and accrued interest under a convertible promissory note into ordinary shares at $1.50 per share.